HK1207004A1 - Treatment of mild and moderated alzheimers disease - Google Patents
Treatment of mild and moderated alzheimers diseaseInfo
- Publication number
- HK1207004A1 HK1207004A1 HK15107776.8A HK15107776A HK1207004A1 HK 1207004 A1 HK1207004 A1 HK 1207004A1 HK 15107776 A HK15107776 A HK 15107776A HK 1207004 A1 HK1207004 A1 HK 1207004A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- moderated
- mild
- treatment
- alzheimers disease
- alzheimers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261710229P | 2012-10-05 | 2012-10-05 | |
| PCT/US2013/062964 WO2014055588A1 (en) | 2012-10-05 | 2013-10-02 | Treatment of mild and moderate alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1207004A1 true HK1207004A1 (en) | 2016-01-22 |
Family
ID=49354960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15107776.8A HK1207004A1 (en) | 2012-10-05 | 2015-08-11 | Treatment of mild and moderated alzheimers disease |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2903606A1 (es) |
| JP (2) | JP6566868B2 (es) |
| KR (1) | KR20150064743A (es) |
| CN (2) | CN110292638A (es) |
| AU (2) | AU2013327450B2 (es) |
| BR (1) | BR112015007641A8 (es) |
| CA (1) | CA2886785C (es) |
| EA (1) | EA201590687A1 (es) |
| HK (1) | HK1207004A1 (es) |
| IL (1) | IL237730B (es) |
| IN (1) | IN2015DN03734A (es) |
| MX (1) | MX2015003732A (es) |
| NZ (2) | NZ705813A (es) |
| SG (2) | SG11201502210VA (es) |
| WO (1) | WO2014055588A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019190823A1 (en) * | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| WO2019190822A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| EP3864008A1 (en) | 2018-10-10 | 2021-08-18 | vTv Therapeutics LLC | Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine |
| WO2020086388A1 (en) * | 2018-10-22 | 2020-04-30 | Vtv Therapeutics Llc | Glucokinase activator compositions for the treatment of cognitive impairment |
| JP7327788B2 (ja) * | 2019-08-06 | 2023-08-16 | 学校法人福岡大学 | 糖化産物生成抑制剤及び医薬組成物 |
| CN114716551B (zh) * | 2021-11-12 | 2023-01-24 | 深圳市人民医院 | 靶向rage的纳米抗体及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1482931B1 (en) * | 2002-03-05 | 2011-10-19 | TransTech Pharma, Inc. | Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage |
| EP1635823A1 (en) * | 2003-05-20 | 2006-03-22 | TransTech Pharma Inc. | Rage antagonists as agents to reverse amyloidosis and diseases associated therewith |
| EP1707203A1 (en) * | 2005-04-01 | 2006-10-04 | Bioprojet | Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands |
| CA2681864A1 (en) * | 2007-04-05 | 2008-10-16 | Transtech Pharma, Inc. | Crystalline forms i and ii of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine |
| CN101663280A (zh) * | 2007-04-05 | 2010-03-03 | 转化技术制药公司 | [3-(4-{2-丁基-1-[4-(4-氯-苯氧基)-苯基]-1h-咪唑-4-基}-苯氧基)-丙基]-二乙基-胺的晶型ⅰ和ⅱ |
| WO2008153957A1 (en) * | 2007-06-07 | 2008-12-18 | The Trustees Of Columbia University In The City Of New York | Uses of rage antagonists for treating obesity and related diseases |
| US20090221554A1 (en) * | 2008-02-28 | 2009-09-03 | Zenyaku Kogyo Kabushiki Kaisha | Method of treating cognitive impairment |
| US8933040B2 (en) * | 2010-11-08 | 2015-01-13 | Craig A. Coburn | Selective glycosidase inhibitors and uses thereof |
-
2013
- 2013-10-02 IN IN3734DEN2015 patent/IN2015DN03734A/en unknown
- 2013-10-02 EP EP13776676.2A patent/EP2903606A1/en not_active Withdrawn
- 2013-10-02 WO PCT/US2013/062964 patent/WO2014055588A1/en active Application Filing
- 2013-10-02 CN CN201910466681.3A patent/CN110292638A/zh active Pending
- 2013-10-02 JP JP2015535750A patent/JP6566868B2/ja active Active
- 2013-10-02 CN CN201380051206.0A patent/CN104703592A/zh active Pending
- 2013-10-02 CA CA2886785A patent/CA2886785C/en active Active
- 2013-10-02 MX MX2015003732A patent/MX2015003732A/es active IP Right Grant
- 2013-10-02 EA EA201590687A patent/EA201590687A1/ru unknown
- 2013-10-02 SG SG11201502210VA patent/SG11201502210VA/en unknown
- 2013-10-02 BR BR112015007641A patent/BR112015007641A8/pt active Search and Examination
- 2013-10-02 NZ NZ705813A patent/NZ705813A/en unknown
- 2013-10-02 AU AU2013327450A patent/AU2013327450B2/en active Active
- 2013-10-02 KR KR1020157011366A patent/KR20150064743A/ko not_active Application Discontinuation
- 2013-10-02 NZ NZ739521A patent/NZ739521A/en unknown
- 2013-10-02 SG SG10201702648YA patent/SG10201702648YA/en unknown
-
2015
- 2015-03-12 IL IL237730A patent/IL237730B/en active IP Right Grant
- 2015-08-11 HK HK15107776.8A patent/HK1207004A1/xx unknown
-
2018
- 2018-05-16 AU AU2018203434A patent/AU2018203434A1/en not_active Abandoned
-
2019
- 2019-05-23 JP JP2019096786A patent/JP6894940B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104703592A (zh) | 2015-06-10 |
| JP2019163301A (ja) | 2019-09-26 |
| CA2886785C (en) | 2022-06-07 |
| AU2013327450B2 (en) | 2018-07-12 |
| MX2015003732A (es) | 2015-09-23 |
| NZ705813A (en) | 2018-02-23 |
| BR112015007641A2 (pt) | 2017-07-04 |
| NZ739521A (en) | 2019-06-28 |
| JP6894940B2 (ja) | 2021-06-30 |
| SG10201702648YA (en) | 2017-04-27 |
| IN2015DN03734A (es) | 2015-09-18 |
| CN110292638A (zh) | 2019-10-01 |
| EA201590687A1 (ru) | 2015-09-30 |
| AU2018203434A1 (en) | 2018-06-07 |
| WO2014055588A1 (en) | 2014-04-10 |
| SG11201502210VA (en) | 2015-04-29 |
| JP6566868B2 (ja) | 2019-08-28 |
| EP2903606A1 (en) | 2015-08-12 |
| IL237730B (en) | 2018-10-31 |
| AU2013327450A1 (en) | 2015-05-14 |
| BR112015007641A8 (pt) | 2018-04-03 |
| CA2886785A1 (en) | 2014-04-10 |
| KR20150064743A (ko) | 2015-06-11 |
| JP2015535850A (ja) | 2015-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1212217A1 (en) | Methods of treating alzheimers disease and pharmaceutical compositions thereof | |
| HK1211844A1 (en) | Treatment of pulmonary disease | |
| EP2890815A4 (en) | METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
| HK1207403A1 (en) | Biomarkers to identify patients that will respond to treatment and treating such patients | |
| HK1203566A1 (en) | Methods and compositions for treating huntingtons disease | |
| EP2890440A4 (en) | DEVICES AND METHOD FOR THE TREATMENT OF VASCULAR DISEASES | |
| EP2906143A4 (en) | SYSTEM AND METHOD FOR CARDIAC TREATMENT | |
| HK1204450A1 (en) | Methods of treating celiac disease | |
| EP2958936A4 (en) | METHOD AND COMPOSITIONS FOR TREATING CORI DISEASE | |
| EP2819687A4 (en) | COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL VASCULAR DISEASE | |
| HK1200348A1 (en) | Methods and materials for treatment of pompes disease | |
| EP2874647A4 (en) | METHOD FOR DIAGNOSIS AND TREATMENT | |
| DK3292875T3 (en) | Compositions and methods for treating diseases | |
| EP2700652A4 (en) | DIAGNOSIS AND TREATMENT OF CANCER BY ANTI-ITM2A ANTIBODIES | |
| HK1207004A1 (en) | Treatment of mild and moderated alzheimers disease | |
| HK1215173A1 (zh) | 治療金黃色葡萄球菌相關疾病的方法 | |
| IL234606A0 (en) | Innovative methods and compounds for the treatment of diseases | |
| HK1208598A1 (en) | Methods and compositions for treating pain | |
| ZA201501503B (en) | Bio-inoculant and use thereof for treatment of effluents | |
| EP2670438A4 (en) | SELECTION AND TREATMENT OF PATIENTS | |
| EP2934543A4 (en) | STIMULATION AND INCREASE IN TISSUE REGENERATION | |
| EP2885008A4 (en) | COMPOSITIONS AND METHODS OF TREATING PERIPHERAL ARTERY DISEASE | |
| GB201212084D0 (en) | Tropomyosin isoforms related to alzheimers disease and mild cognitive impairment | |
| HK1213584A1 (zh) | 用於治療癌症的 抗體及方法 | |
| EP2888355A4 (en) | MODIFIED HUMAN ROTAVIRUS AND USES THEREOF |